



Pharmaceuticals Limited

Registered & Corporate Office :

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,

Opp. SBI Executive Enclave, Banjara Hills,

Hyderabad - 500 034, Telangana, INDIA.

Tel : +91-40-2525 9999, Fax : +91-40-2525 9889

CIN : L24239TG1987PLC008066

Email: info@smspharma.com, www.smspharma.com

Date: 17th March, 2022

To,
Listing / Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400 001

Listing / Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C-1, Block G,
Bandra-Kurla Complex, Bandra (East),
Mumbai- 400051

BSE Code: – 532815

NSE Code: SMSPHARMA

Sub: Press Release – Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We are enclosing herewith Press Release dated 17th March, 2022 regarding the Company receives non-exclusive license to manufacture and supply of Nirmatrelvir (an oral COVID-19 medicine) through the Medicine Patent Pool (MPP)

Kindly take the same on record.

Thanking you.

Yours Faithfully,
For SMS Pharmaceuticals Limited



T. Lakshmi Narayana
Chief Financial Officer

Press Release

SMS Pharmaceuticals Limited receives non-exclusive license to manufacture and supply of nirmatrelvir (an oral COVID-19 medicine) through the Medicine Patent Pool (MPP)

Hyderabad, March 17, 2022: SMS Pharmaceuticals Limited has received a non-exclusive license through the Medicines Patent Pool (MPP) to manufacture nirmatrelvir, an oral antiviral COVID-19 medicine developed by Pfizer, to increase broad access of treatment in 95 low- and middle- income countries .

Pfizer previously announced that the trial of its novel COVID-19 oral antiviral candidate PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets) shows the medicine significantly reduced the risk of hospitalization or death for any cause by 89% compared to placebo in non-hospitalized, high-risk adult patients with COVID-19 treated within three days of symptom onset. Pfizer has signed a voluntary licensing with MPP allowing the MPP to grant sub-licences for the manufacture of generic versions of its COVID-19 oral treatment to qualified generic drug manufacturers for supply to 95 low- and middle-income countries including India. The agreement will allow MPP to enable additional production and distribution of the medicine, pending regulatory authorization or approval, by granting sub-licenses to qualified generic medicine manufacturers, with the goal of increasing global access.

Commenting on this Mr. P. Vamsi Krishna, Executive Director – SMS Pharmaceuticals Limited said, *“It is our pleasure and pride to be a part of humanitarian mission by MPP and Pfizer with the goal of providing broad and equitable access of low-cost oral COVID-19 medicine for low- and middle-income countries. With the ever-evolving, dynamic covid-19 related challenges across the globe, SMS Pharma is committed to develop and manufacture affordable and high-quality generic breakthrough products that will help overcome current obstacles and future barriers to sustainable health for the people.*

We firmly believe in our legacy to receive licensing for products that require high-quality efficiency while frugally maintaining lower costs and faster turnaround time. This is a testament to SMS Pharma’s reputation and manufacturing capabilities.”

About SMS Pharmaceuticals Limited

Established in 1990, SMS Pharma is a global player in API and intermediates manufacturing having a strong research and manufacturing team supported by state-of-the-art facilities. The Company has capabilities in wide range of APIs / intermediates and has handled varied process reactions and reactor volumes up to 2,000 KL. The company undertakes contract manufacturing of API, Intermediates (advanced and basic) offering a competitive advantage to its clients especially in late stage lifecycle of products. The Company has demonstrated its manufacturing excellence over the past 2 decades in a broad portfolio of therapeutic segments by being a trusted partner to a customer base in over 70 countries (including clientele in top 20 pharma companies). With 2 manufacturing facilities (two USFDA inspected), 2 pilot plants, 1 R&D center and 1 USFDA approved Independent Testing Laboratory, SMS Pharma is an ideal partner for custom synthesis, process development and mass manufacturing of customer’s own discovery products.

For more information, please visit smspharma.com

Safe Harbor

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For more information please contact:



SMS Pharmaceuticals Limited
CIN: L24239TG1987PLC008066

Mr. Thirumalesh Tumma
Email: cs@smspharma.com

Contact no.: +91 9100123244

SGA Strategic Growth Advisors

Strategic Growth Advisors Pvt. Ltd.
CIN: U74140MH2010PTC204285

Mr. Jigar Kavaiya / Mr. Chinmay Madgulkar
Email: jigar.kavaiya@sgapl.net / chinmay.m@sgapl.net

Contact no.: +91 9920602034 / +91 9860088296